ESH 2017 | Efficacy of first generation FLT3 inhibitors for AML

Miguel Sanz

New molecules targeting specific gene mutations are showing great potential for precisely treating diseases and lowering the toxicity of treatment. In this interview, recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Miguel Sanz, MD, of the University Hospital La Fe, Valencia, Spain, discusses his talk at the conference, where he discussed the use of the FLT3 inhibitor midostaurin, which was recently approved after the RATIFY clinical trial (NCT00651261), alongside standard chemotherapy for the treatment of AML. Dr Sanz also touches upon the improvements that could be made to a treatment when developing next generation versions.

Share this video